-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $200

Benzinga·07/17/2026 14:24:59
语音播报
Wells Fargo analyst Mohit Bansal maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $175 to $200.